Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.32 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.32 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718133 | 0.88 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3530695 | 0.88 | RAF1 (0.46) | RAF1BRAF | |
| SCHEMBL2720028 | 0.86 | MAPK13 (0.33) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| Dilmapimod SCHEMBL1065268 | 0.86 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3535843 | 0.85 | RAF1 (0.36) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1066098 | 0.84 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2720026 | 0.84 | RAF1 (0.46) | MAPK14RAF1BRAF | |
| SCHEMBL3536611 | 0.84 | RAF1 (0.37) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3526785 | 0.83 | RAF1 (0.46) | MAPK14RAF1BRAF | |
| SCHEMBL3531127 | 0.83 | RAF1 (0.46) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| EP-2447266-A1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LIMITED (GB) | 2012-05-02 | — | — | EP | disclosed |
| EP-2447266-A1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LIMITED (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20100144755-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144755-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-1868611-A4 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-20090069318-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069318-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069318-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| WO-2006104915-A9 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LTD (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2006104915-A9 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LTD (GB) | 2008-01-03 | — | — | WO | disclosed |
| EP-1868611-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007147103-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104915-A2 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144755-A1 | Novel Compounds | MAPKAPK2, CDC42BPB, MAPK8 | MAPK14 35/4885MAPK13 44/4885MAPK12 83/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | MAPK14 35/4885MAPK13 44/4885MAPK12 83/4885 |
| US-20090069318-A1 | Novel Compounds | MAPKAPK2, MAPK8, MAPKAPK3 | MAPK14 43/4885MAPK13 44/4885MAPK12 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.